HK1199021A1 - Quinazoline compounds as serine threonine kinase inhibitors - Google Patents
Quinazoline compounds as serine threonine kinase inhibitorsInfo
- Publication number
- HK1199021A1 HK1199021A1 HK14112451.1A HK14112451A HK1199021A1 HK 1199021 A1 HK1199021 A1 HK 1199021A1 HK 14112451 A HK14112451 A HK 14112451A HK 1199021 A1 HK1199021 A1 HK 1199021A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- threonine kinase
- serine threonine
- quinazoline compounds
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515165P | 2011-08-04 | 2011-08-04 | |
| PCT/US2012/049551 WO2013020062A1 (en) | 2011-08-04 | 2012-08-03 | Quinazoline compounds as serine/threonine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1199021A1 true HK1199021A1 (en) | 2015-06-19 |
Family
ID=47003195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112451.1A HK1199021A1 (en) | 2011-08-04 | 2014-12-10 | Quinazoline compounds as serine threonine kinase inhibitors |
| HK14112740.2A HK1199248A1 (zh) | 2011-08-04 | 2014-12-19 | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112740.2A HK1199248A1 (zh) | 2011-08-04 | 2014-12-19 | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9187462B2 (es) |
| EP (1) | EP2739618B1 (es) |
| JP (1) | JP6097289B2 (es) |
| KR (1) | KR101979042B1 (es) |
| CN (1) | CN103958502B (es) |
| BR (1) | BR112014002675A2 (es) |
| CA (1) | CA2844058A1 (es) |
| ES (1) | ES2552989T3 (es) |
| HK (2) | HK1199021A1 (es) |
| MX (1) | MX340756B (es) |
| RU (1) | RU2014108140A (es) |
| WO (1) | WO2013020062A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013021896A2 (pt) | 2011-02-28 | 2016-11-08 | Array Biopharma Inc | inibidores de serina/treonina cinase |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| PL3321262T3 (pl) | 2012-03-01 | 2021-06-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| AR092253A1 (es) | 2012-08-27 | 2015-04-08 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| WO2014060395A1 (en) | 2012-10-16 | 2014-04-24 | F. Hoffmann-La Roche Ag | Serine/threonine kinase inhibitors |
| CN103254142B (zh) * | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JP6449293B2 (ja) | 2013-12-06 | 2019-01-09 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| CN105980387B (zh) * | 2013-12-30 | 2019-04-19 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
| JP6487925B2 (ja) | 2013-12-30 | 2019-03-20 | ジェネンテック， インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| US11447493B2 (en) | 2018-05-02 | 2022-09-20 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
| KR20210040368A (ko) | 2018-06-29 | 2021-04-13 | 킨네이트 바이오파마 인크. | 사이클린 의존성 키나제의 억제제 |
| AU2019372046B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2021080929A1 (en) * | 2019-10-25 | 2021-04-29 | Merck Sharp & Dohme Corp. | N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| CN115448864B (zh) * | 2022-08-26 | 2023-12-22 | 上海方予健康医药科技有限公司 | 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693114B2 (en) | 1993-10-01 | 1998-06-25 | Novartis Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JP2002514196A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジノンおよびピリドン化合物ならびに使用方法 |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| RU2277911C2 (ru) | 2000-02-25 | 2006-06-20 | Ф.Хоффманн-Ля Рош Аг | Модуляторы аденозиновых рецепторов |
| KR20070058022A (ko) | 2000-04-26 | 2007-06-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 배변을 촉진하는 의약 조성물 |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MXPA04011470A (es) | 2002-05-21 | 2005-02-14 | Amgen Inc | Compuestos heterociclicos sustituidos y metodos de uso. |
| JP4530852B2 (ja) | 2002-07-15 | 2010-08-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病治療のためのピペリジノピリミジンジペプチジルペプチダーゼ阻害剤 |
| TW200533357A (en) | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| EA010369B1 (ru) * | 2004-02-04 | 2008-08-29 | Пфайзер Продактс Инк. | Замещенные хинолиновые соединения |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2006021458A2 (en) | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| AR053712A1 (es) | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| CN101415674A (zh) | 2006-02-16 | 2009-04-22 | 先灵公司 | 作为erk抑制剂的吡咯烷衍生物 |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| DE102006035202A1 (de) | 2006-07-29 | 2008-01-31 | Lanxess Deutschland Gmbh | Konservierungsmittel auf Basis von Carbonsäureanhydriden |
| JP2010501540A (ja) | 2006-08-23 | 2010-01-21 | ファイザー・プロダクツ・インク | Ｇｓｋ−３阻害剤としてのピリミドン化合物 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| US20100048597A1 (en) | 2006-12-22 | 2010-02-25 | Novartis Ag | Organic Compounds and Their Uses |
| EP2200436B1 (en) | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| AU2008324833A1 (en) | 2007-11-06 | 2009-05-14 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic amines |
| WO2009146034A2 (en) * | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| KR20110022089A (ko) | 2008-06-27 | 2011-03-04 | 노파르티스 아게 | 유기 화합물 |
| JP2011526299A (ja) | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス， インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| US8940891B2 (en) | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| BR112013021896A2 (pt) * | 2011-02-28 | 2016-11-08 | Array Biopharma Inc | inibidores de serina/treonina cinase |
| ES2552989T3 (es) | 2011-08-04 | 2015-12-03 | Array Biopharma, Inc. | Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina |
| PL3321262T3 (pl) | 2012-03-01 | 2021-06-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| AR092253A1 (es) | 2012-08-27 | 2015-04-08 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
-
2012
- 2012-08-03 ES ES12769775.3T patent/ES2552989T3/es active Active
- 2012-08-03 JP JP2014524111A patent/JP6097289B2/ja active Active
- 2012-08-03 RU RU2014108140/04A patent/RU2014108140A/ru not_active Application Discontinuation
- 2012-08-03 WO PCT/US2012/049551 patent/WO2013020062A1/en active Application Filing
- 2012-08-03 CA CA2844058A patent/CA2844058A1/en not_active Abandoned
- 2012-08-03 EP EP12769775.3A patent/EP2739618B1/en active Active
- 2012-08-03 CN CN201280049268.3A patent/CN103958502B/zh active Active
- 2012-08-03 MX MX2014001389A patent/MX340756B/es active IP Right Grant
- 2012-08-03 US US14/237,143 patent/US9187462B2/en active Active
- 2012-08-03 KR KR1020147005731A patent/KR101979042B1/ko active IP Right Grant
- 2012-08-03 BR BR112014002675A patent/BR112014002675A2/pt not_active IP Right Cessation
-
2014
- 2014-12-10 HK HK14112451.1A patent/HK1199021A1/xx unknown
- 2014-12-19 HK HK14112740.2A patent/HK1199248A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX340756B (es) | 2016-07-25 |
| JP2014521696A (ja) | 2014-08-28 |
| MX2014001389A (es) | 2014-11-13 |
| JP6097289B2 (ja) | 2017-03-15 |
| EP2739618A1 (en) | 2014-06-11 |
| CN103958502B (zh) | 2016-02-10 |
| CN103958502A (zh) | 2014-07-30 |
| CA2844058A1 (en) | 2013-02-07 |
| KR101979042B1 (ko) | 2019-05-15 |
| US9187462B2 (en) | 2015-11-17 |
| RU2014108140A (ru) | 2015-09-10 |
| EP2739618B1 (en) | 2015-09-16 |
| ES2552989T3 (es) | 2015-12-03 |
| BR112014002675A2 (pt) | 2017-02-21 |
| HK1199248A1 (zh) | 2015-06-26 |
| US20150087664A1 (en) | 2015-03-26 |
| KR20140062057A (ko) | 2014-05-22 |
| WO2013020062A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254429A1 (zh) | 絲氨酸/蘇氨酸激酶抑制劑 | |
| IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| HK1199248A1 (zh) | 作為絲氨酸/蘇氨酸激酶抑制劑的喹唑啉化合物 | |
| HK1215253A1 (zh) | 作為激酶抑制劑的吡咯並嘧啶化合物 | |
| IL227399A0 (en) | Novel azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | |
| HK1192247A1 (zh) | 作為激酶抑制劑的雜環化合物 | |
| HK1199880A1 (en) | Benzonitrile derivatives as kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| HK1211574A1 (en) | Serine threonine kinase inhibitors | |
| EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS |